Proenkephalin A 119-159 Predicts Early and Successful Liberation from Renal Replacement Therapy in Critically Ill Patients with Acute Kidney Injury: a Post Hoc Analysis of the ELAIN Trial

Overview

Journal Crit Care

Specialty Critical Care

Date 2022 Nov 1

PMID 36316692

Authors

Thilo von Groote

Felix Albert

Melanie Meersch

Raphael Koch

Christian Porschen

Oliver Hartmann

Deborah Bergmann

Peter Pickkers

Alexander Zarbock

Affiliations

Soon will be listed here.

Abstract

Background: Renal replacement therapy (RRT) remains the key rescue therapy for critically ill patients with severe acute kidney injury (AKI). However, there are currently no tools available to predict successful liberation from RRT. Biomarkers may allow for risk stratification and individualization of treatment strategies. Proenkephalin A 119-159 (penKid) has been suggested as a promising marker of kidney function in the context of AKI, but has not yet been evaluated for RRT liberation in critically ill patients with AKI.

Methods: This post hoc analysis included 210 patients from the randomized clinical ELAIN trial and penKid levels were measured in the blood of these patients. Competing risk time-to-event analyses were performed for pre-RRT penKid at initiation of RRT and in a landmark analysis at day 3 after initiation of RRT. Competing risk endpoints were successful liberation from RRT or death without prior liberation from RRT.

Results: Low pre-RRT penKid levels (penKid ≤ 89 pmol/l) at RRT initiation were associated with early and successful liberation from RRT compared to patients with high pre-RRT penKid levels (subdistribution hazard ratio (sHR) 1.83, 95%CI 1.26-2.67, p = 0.002, estimated 28d-cumulative incidence function (28d-CIF) of successful liberation from RRT 61% vs. 45%, p = 0.022). This association persisted in the landmark analysis on day 3 of RRT (sHR 1.78, 95%CI 1.17-2.71, p = 0.007, 28d-CIF of successful liberation from RRT 67% vs. 47%, p = 0.018). For both time points, no difference in the competing event of death was detected.

Conclusions: In critically ill patients with RRT-dependent AKI, plasma penKid appears to be a useful biomarker for the prediction of shorter duration and successful liberation from RRT and may allow an individualized approach to guide strategies of RRT liberation in critically ill patients with RRT-dependent AKI.

Trial Registration: The ELAIN trial was prospectively registered at the German Clinical Trial Registry (Identifier: DRKS00004367) on 28th of May 2013.

Citing Articles

Can Novel Biomarkers Effectively Predict Acute Kidney Injury in Liver or Kidney Transplant Recipients?.

Zywno H, Figiel W, Grat M, Nazarewski S, Galazka Z, Malyszko J Int J Mol Sci. 2024; 25(22).

PMID: 39596140 PMC: 11593440. DOI: 10.3390/ijms252212072.

Proenkephalin A 119-159 in Perioperative and Intensive Care-A Promising Biomarker or Merely Another Option?.

Walczak-Wieteska P, Zuzda K, Malyszko J, Andruszkiewicz P Diagnostics (Basel). 2024; 14(21).

PMID: 39518330 PMC: 11545452. DOI: 10.3390/diagnostics14212364.

Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach.

Pan S, Huang T, Jiang Z, Lin L, Tsai I, Wu T Kidney Res Clin Pract. 2024; 43(4):406-416.

PMID: 38934037 PMC: 11237330. DOI: 10.23876/j.krcp.23.289.

Predictive approach for liberation from acute dialysis in ICU patients using interpretable machine learning.

Wang T, Huang C, Wu C, Chen C, Wang M, Chao W Sci Rep. 2024; 14(1):13142.

PMID: 38849453 PMC: 11161460. DOI: 10.1038/s41598-024-63992-y.

From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease.

Yeh T, Tu K, Wang H, Chen J Int J Mol Sci. 2024; 25(3).

PMID: 38339031 PMC: 10855633. DOI: 10.3390/ijms25031755.

References

Koyner J, Chawla L, Bihorac A, Gunnerson K, Schroeder R, Demirjian S . Performance of a Standardized Clinical Assay for Urinary C-C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury. Kidney360. 2022; 3(7):1158-1168. PMC: 9337886. DOI: 10.34067/KID.0008002021. View

Korkeila M, Ruokonen E, Takala J . Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care. Intensive Care Med. 2001; 26(12):1824-31. DOI: 10.1007/s001340000726. View

Bagshaw S, Al-Khafaji A, Artigas A, Davison D, Haase M, Lissauer M . External validation of urinary C-C motif chemokine ligand 14 (CCL14) for prediction of persistent acute kidney injury. Crit Care. 2021; 25(1):185. PMC: 8166095. DOI: 10.1186/s13054-021-03618-1. View

Chen X, Chen Z, Wei T, Li P, Zhang L, Fu P . The Effect of Serum Neutrophil Gelatinase-Associated Lipocalin on the Discontinuation of Continuous Renal Replacement Therapy in Critically Ill Patients with Acute Kidney Injury. Blood Purif. 2019; 48(1):10-17. DOI: 10.1159/000499026. View

Oeyen S, De Corte W, Benoit D, Annemans L, Dhondt A, Vanholder R . Long-term quality of life in critically ill patients with acute kidney injury treated with renal replacement therapy: a matched cohort study. Crit Care. 2015; 19:289. PMC: 4527359. DOI: 10.1186/s13054-015-1004-8. View

Prentice R, Kalbfleisch J, Peterson Jr A, Flournoy N, Farewell V, Breslow N . The analysis of failure times in the presence of competing risks. Biometrics. 1978; 34(4):541-54. View

Sezen S, Kenigs V, Kapusta D . Renal excretory responses produced by the delta opioid agonist, BW373U86, in conscious rats. J Pharmacol Exp Ther. 1998; 287(1):238-45. View

Uchino S, Kellum J, Bellomo R, Doig G, Morimatsu H, Morgera S . Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294(7):813-8. DOI: 10.1001/jama.294.7.813. View

Yang T, Zhao Y, Liu Q, Han M, Sun S, Lin L . Prognostic Biomarkers at Discontinuation of Renal Replacement Therapy in Acute Kidney Injury Patients in the Intensive Care Unit. Blood Purif. 2016; 42(4):347-348. DOI: 10.1159/000452242. View

10.

Donato L, Meeusen J, Lieske J, Bergmann D, Sparwasser A, Jaffe A . Analytical performance of an immunoassay to measure proenkephalin. Clin Biochem. 2018; 58:72-77. DOI: 10.1016/j.clinbiochem.2018.05.010. View

11.

Kim C, Bae E, Ma S, Kim S . A Prospective Observational Study on the Predictive Value of Serum Cystatin C for Successful Weaning from Continuous Renal Replacement Therapy. Kidney Blood Press Res. 2018; 43(3):872-881. DOI: 10.1159/000490335. View

12.

Han S, Bae E, Song S, Kim D, Kim Y, Han J . NT-proBNP Is Predictive of the Weaning from Continuous Renal Replacement Therapy. Tohoku J Exp Med. 2016; 239(1):1-8. DOI: 10.1620/tjem.239.1. View

13.

Caironi P, Latini R, Struck J, Hartmann O, Bergmann A, Bellato V . Circulating Proenkephalin, Acute Kidney Injury, and Its Improvement in Patients with Severe Sepsis or Shock. Clin Chem. 2018; 64(9):1361-1369. DOI: 10.1373/clinchem.2018.288068. View

14.

Aniort J, Ait Hssain A, Pereira B, Coupez E, Pioche P, Leroy C . Daily urinary urea excretion to guide intermittent hemodialysis weaning in critically ill patients. Crit Care. 2016; 20:43. PMC: 4761179. DOI: 10.1186/s13054-016-1225-5. View

15.

Hoste E, Bihorac A, Al-Khafaji A, Ortega L, Ostermann M, Haase M . Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med. 2020; 46(5):943-953. PMC: 7210248. DOI: 10.1007/s00134-019-05919-0. View

16.

Hoste E, Bagshaw S, Bellomo R, Cely C, Colman R, Cruz D . Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015; 41(8):1411-23. DOI: 10.1007/s00134-015-3934-7. View

17.

Katulka R, Al Saadon A, Sebastianski M, Featherstone R, Vandermeer B, Silver S . Determining the optimal time for liberation from renal replacement therapy in critically ill patients: a systematic review and meta-analysis (DOnE RRT). Crit Care. 2020; 24(1):50. PMC: 7020497. DOI: 10.1186/s13054-020-2751-8. View

18.

Denning G, Ackermann L, Barna T, Armstrong J, Stoll L, Weintraub N . Proenkephalin expression and enkephalin release are widely observed in non-neuronal tissues. Peptides. 2007; 29(1):83-92. DOI: 10.1016/j.peptides.2007.11.004. View

19.

Chen J, Lee T, Lee C, Chang C . Using lipocalin as a prognostic biomarker in acute kidney injury. Expert Rev Mol Diagn. 2021; 21(5):455-464. DOI: 10.1080/14737159.2021.1917384. View

20.

Yang T, Sun S, Zhao Y, Liu Q, Han M, Lin L . Biomarkers upon discontinuation of renal replacement therapy predict 60-day survival and renal recovery in critically ill patients with acute kidney injury. Hemodial Int. 2017; 22(1):56-65. DOI: 10.1111/hdi.12532. View